Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the transaction, the vice president now directly owns 24,883 shares in the company, valued at approximately $261,022.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
TEVA stock opened at $10.26 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. The firm’s 50-day simple moving average is $8.96 and its 200 day simple moving average is $8.37. The stock has a market cap of $11.38 billion, a PE ratio of 3.66, a price-to-earnings-growth ratio of 1.12 and a beta of 1.82. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $6.07 and a fifty-two week high of $22.02.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The firm had revenue of $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.
TEVA has been the subject of several research analyst reports. SunTrust Banks lowered their price objective on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a report on Thursday, August 8th. UBS Group set a $8.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, August 16th. Guggenheim assumed coverage on Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They issued a “neutral” rating for the company. BMO Capital Markets decreased their target price on Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating for the company in a research report on Friday, August 9th. Finally, Raymond James lowered their price target on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have issued a buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and an average target price of $11.22.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.